TY  - JOUR
U1  - Zeitschriftenartikel, wissenschaftlich - begutachtet (reviewed)
A1  - Zhang, Ying
A1  - Sharma, Amit
A1  - Weiher, Hans
A1  - Schmid, Matthias
A1  - Kristiansen, Glen
A1  - Schmidt-Wolf, Ingo G. H.
T1  - Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials
JF  - Cancers
N2  - Cancer is a complex disease where resistance to therapies and relapses often pose a serious clinical challenge. The scenario is even more complicated when the cancer type itself is heterogeneous in nature, e.g., lymphoma, a cancer of the lymphocytes which constitutes more than 70 different subtypes. Indeed, the treatment options continue to expand in lymphomas. Herein, we provide insights into lymphoma-specific clinical trials based on cytokine-induced killer (CIK) cell therapy and other pre-clinical lymphoma models where CIK cells have been used along with other synergetic tumor-targeting immune modules to improve their therapeutic potential. From a broader perspective, we will highlight that CIK cell therapy has potential, and in this rapidly evolving landscape of cancer therapies its optimization (as a personalized therapeutic approach) will be beneficial in lymphomas.
KW  - clinical study
KW  - cytokine-induced killer cells
KW  - immunotherapy
KW  - lymphoma
UN  - https://nbn-resolving.org/urn:nbn:de:hbz:1044-opus-60290
SN  - 2072-6694
SS  - 2072-6694
U6  - https://doi.org/10.3390/cancers13236007
DO  - https://doi.org/10.3390/cancers13236007
PM  - 34885117
VL  - 13
IS  - 23
SP  - 13
S1  - 13
PB  - MDPI
CY  - Basel
ER  -